Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Routine Newborn Blood Spots Can Measure GBS Antibody Levels

By LabMedica International staff writers
Posted on 05 Oct 2026

Group B Streptococcus (GBS) can cause serious infections in newborns. More...

Protecting infants remains challenging because immune protection may depend on antibodies transferred from mother to baby before birth. In Denmark, newborns routinely undergo heel-prick blood sampling a few days after delivery to screen for rare congenital diseases. A new study shows that these routinely collected samples can also measure antibodies against GBS.

Aarhus University (Aarhus, Denmark) researchers evaluated heel-prick blood samples, also described as PKU cards, as a practical alternative to standard newborn blood samples for assessing GBS antibody levels. The method measures immunoglobulin G (IgG) antibodies against GBS alpha-like surface proteins (AlpN). The aim was to determine whether antibody concentrations in PKU cards and umbilical cord serum reflect concentrations found in serum from the newborn.

The study was a small proof-of-concept, cross-sectional study. Pregnant women were enrolled at 35–37 weeks of gestation during routine midwife consultations at Kolding Hospital between June 2023 and January 2024. The researchers compared GBS antibody measurements from heel-prick samples and umbilical cord blood with measurements from standard blood samples taken from the same newborns.

The results showed that heel-prick samples closely reflected the level of GBS antibodies found in standard blood samples. Umbilical cord blood also generally provided a good indication of the baby’s antibody level. The findings suggest that existing newborn blood sampling material can be used to study how many maternal antibodies against GBS are transferred before birth.

The main Danish collaborators were Lillebælt Hospital/Kolding and Vejle Hospital, Aarhus University, Aarhus University Hospital, and the University of Southern Denmark. The main international collaborators were MinervaX and the Centre for Neonatal and Paediatric Infection/Vaccine Institute, University of London. The research team has begun investigating the relationship between newborn GBS antibody levels and infection risk, with plans to expand the work using a larger group of blood samples from different populations and countries.

The findings are particularly relevant to researchers and vaccine developers working on GBS vaccines for pregnant women. The team aims to determine what level of antibodies is required to protect newborns. 

“To improve our ability to protect newborns against serious GBS infections, we need to know how effectively mothers can transfer antibodies to their babies before birth. We can now gain that knowledge, having shown that the heel-prick samples already collected from newborns can be used to measure antibody levels,” said May Murra, a postdoc at the Department of Biomedicine at Aarhus University.

Related Links
Aarhus University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.